A trial treating 16 adult ALL patients with Cy 1.5 to 3.0 g/m2 as LD followed by an anti-CD19 CD28-CD3z was able to achieve an unprecedented complete response rate (CRR) of 78% (105). This evidence concerns the gene CD28 and acute lymphoblastic leukemia.